Latest News & Updates

Breaking News

  • 9 hours ago

  • Simantini Singh Deo

Longeveron Inc. Announces Phase 2b Trial Results Published In Cell Stem Cell Showing Laromestrocel (LOMECEL-B®) Improved Physical Function In Frailty Patients At Nine Months
Breaking News
Opus Genetics Announces U.S. Food And Drug Administration Acceptance Of Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia

Simantini Singh Deo

Japan’s Ministry of Health, Labour And Welfare Grants Orphan Drug Status To Rilzabrutinib After Positive Phase 2 Results In IgG4-Related Disease

Simantini Singh Deo

Septerna, Inc. Reports Strong Phase 1 Results For Oral MRGPRX2 NAM SEP-631, Sets Plan For Phase 2 Trials In Chronic Spontaneous Urticaria

Simantini Singh Deo

Roche’s Fenebrutinib Reduces Relapse Rate By 51% In Phase III FENhance 1 Trial For Relapsing Multiple Sclerosis

Vaibhavi M.

Other trending news you may like to read

Longeveron Inc. Announces Phase 2b Trial Results Published In Cell Stem Cell Showing Laromestrocel (LOMECEL-B®) Improved Physical Function In Frailty Patients At Nine Months

LOMECEL-B boosts 6MWT by 63m at 9 months in Phase 2b frailty trial.

Simantini Singh Deo

Pharma Now

Opus Genetics Announces U.S. Food And Drug Administration Acceptance Of Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia

FDA accepts Opus sNDA for phentolamine 0.75% in presbyopia.

Simantini Singh Deo

Pharma Now

Japan’s Ministry of Health, Labour And Welfare Grants Orphan Drug Status To Rilzabrutinib After Positive Phase 2 Results In IgG4-Related Disease

Japan grants orphan status to rilzabrutinib for IgG4-RD.

Simantini Singh Deo

Pharma Now

Septerna, Inc. Reports Strong Phase 1 Results For Oral MRGPRX2 NAM SEP-631, Sets Plan For Phase 2 Trials In Chronic Spontaneous Urticaria

SEP-631 shows strong Phase 1 data; Phase 2b planned in CSU.

Simantini Singh Deo

Pharma Now